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Abstract: Reactive airways dysfunction syndrome is a controversial and poorly understood 
condition produced by inhalational injury from gas, vapors, or fumes. The symptoms mimic 
asthma, but appear unresponsive to asthma treatments. If symptoms persist for more than 
6 months, there is a risk that they can become chronic. For these cases, effective treatments are 
lacking and quality of life is poor. We describe the first use of high-dose vitamin D in a patient 
with this condition, who fulfilled the 1995 American College of Chest Physicians criteria for 
this syndrome. The patient we describe presented an extremely difficult management problem 
and was refractory to conventional treatments, but responded to high-dose oral vitamin D 
supplements.
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Introduction
Reactive airways dysfunction syndrome (RADS) is defined as the sudden onset of 
asthma-like symptoms following high-level exposure to a corrosive gas, vapor, or 
fumes. The term RADS was originally described by Brooks and Lockers in 19811 as 
nonimmunological asthma resulting from exposure to an irritant gas. Given that most 
cases are recognized retrospectively, often with considerable delay, they usually lack 
accurate assessment of the exposure intensity and objective evidence of prior normal 
bronchial hyper-responsiveness required for the diagnosis of RADS.2
The symptoms usually manifest within 24 hours of exposure as bronchitis, with 
ocular or mucus membrane irritation of the upper airway (depending on the agent) and 
often require emergency treatment. The presentation of RADS is different from that 
of true occupational asthma, because it is an acute single event without a significant 
latency period. Many cases occurred after the 9/11 collapse of the New York World 
Trade Center, resulting from the inhalation of fumes and particulate matter.3 The 
American College of Chest Physicians consensus criteria for the diagnosis of RADS 
were agreed in 1995,4 and were:
•	 Documented absence of preceding respiratory complaint
•	 Onset after single exposure incident/accident
•	 Exposure to very high concentration of gas, smoke, fumes, or vapors with irritant 
properties
•	 Onset of symptoms within 24 hours after exposure with persistence for at least 
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•	 Symptoms that simulate asthma with cough, wheeze, and 
dyspnea
•	 Presence of airflow obstruction on pulmonary function ± 
nonspecific bronchial hyper-responsiveness
•	 All other pulmonary disease excluded.
These criteria have been criticized for being overly 
restrictive by Alberts and do Pico.5 The pathology of RADS 
shows nonspecific inflammation, with a cellular infiltrate 
which is primarily lymphocytic with epithelial desquamation.6 
Alberts and Brooks describe the “big bang” mechanism of 
epithelial injury, with activation of nonadrenergic and 
noncholinergic fibers via axon reflexes giving rise to 
neurogenic inflammation, macrophage activation, and 
mast cell degranulation.7 The resulting proinflammatory 
state, with toxic mediators, gives rise to epithelial injury. 
Although most people recover, extensive inflammation and 
epithelial sloughing could reduce receptor thresholds for 
severe ongoing bronchial hyper-reactivity. To date, there are 
no animal models of this disease. The literature suggests that 
RADS should be recognized as a unique form of asthma with 
significant upper airway symptoms that are often ignored but 
appear to be part of the condition.8 There is a growing list of 
recognized causal agents,9 which include:
	•  Household exposure: floor sealants, spray paint, bleaching 
agents, household cleaners containing morpholine.
	•  Chemical: chlorine, sulphuric acid, ammonia, hydrochloric 
acid, acetic acid, phosgene, hydrogen sulphide, sodium 
azide, sodium hypochlorite, toluene di-isocyanates, 
organic solvents.
	•  Industry: paint spraying, metal-coat removers, welding, 
heated plastics or acids, epoxy resins, perfumes, pesticides, 
enzymes, industrial cleaning products, dust or molds in 
silos.
	•	 Other: Fire and smoke inhalation, burning paint fumes, 
tear gas, locomotive exhaust, World Trade Center collapse 
in New York.
There have been few developments in the management of 
this condition. Traditional treatment is the same as that of con-
ventional asthma, despite evidence that patients with RADS 
are less responsive to β2 agonists.10 Long-term outcome is 
not well documented, but if symptoms do not remit within 
6–24 months they are more likely to become persistent.11 
Oral corticosteroids and bronchodilators commenced within 
the first 3 months have had the most favorable outcomes.12,13 
However, some reported case series suggest symptoms may 
be more persistent than originally thought. Demeter et al14 
reported a nine-year follow-up, where nine of 19 patients 
with RADS still had ongoing symptoms, one of whom was 
progressive. Malo assessed mill workers   following   exposure 
to chlorine, and found that 29 of 51 still had bronchial 
hyper-responsiveness over a period of 24 months.15 There 
is a paucity of data regarding therapeutic interventions for 
those with persistent symptoms. The condition appears to 
have an equal male/female   incidence.   Nebulized sodium 
bicarbonate following chlorine gas exposure has been shown 
to improve quality of life and forced expiratory volume in 1 
second (FEV1),16 but not lead to a resolution of   symptoms. 
Lung transplantation has been used for severe ongoing 
symptoms of RADS following the New York World Trade 
Center collapse.17
This report describes a patient with severe unremitting 
symptoms of RADS five years following ammonia exposure, 
and discusses the response to vitamin D.
Case report
A 36-year-old nursing sister was referred to our center with a 
history of incessant cough, shortness of breath, and extreme 
bronchial hyper-reactivity of five years’ duration. Symptoms 
had started following exposure to an ammonia spillage by 
workmen on the floor below the renal unit where she worked 
as a dialysis sister. The unit had to be evacuated and she 
received high level exposure for up to two hours. Later 
that day she developed acute onset of cough, wheeze, and 
mucosal irritation symptoms, and needed to attend Accident 
and Emergency. There she was treated with nebulized 
salbutamol. Over a period of several days, the cough and 
wheeze worsened and she required prednisolone. Initially 
this produced an improvement in symptoms; however, 
over the subsequent year she required multiple courses of 
prednisolone, and commenced inhaled corticosteroids and 
a short-acting β2 agonist. She was seen at a specialist chest 
hospital, but no solution or effective treatment was found, 
and pessimism developed about a likely response to any 
treatment.
Her original assessment showed normal routine blood 
tests, a clear chest radiograph, normal echocardiogram, and 
normal high-resolution computed tomography of her chest. 
Pulmonary function tests had revealed evidence of airways 
obstruction with airway resistance (raw) at 168% of predicted 
and reduced small airway indices. Lung volumes and gas 
transfer measurements were within normal limits. Histamine 
challenge was positive, with a methacholine-provoking 
  concentration for a 20% fall (PC20) of 7.3 mg/mL.
The patient was unable to return to work, and had become 
virtually housebound due to the severity of her symptoms 
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odors. She had no prior respiratory illness, no atopy, and 
was a lifelong nonsmoker. Five years later, at the time of her 
referral to our center, her life quality was extremely poor. She 
was experiencing intractable paroxysms of coughing lasting 
continuously for 4–5 hours, with an incessant background 
cough leading to significant chest wall pain. She recognized 
multiple triggers, including air temperature changes, cigarette 
smoke, perfumes, cleaning products, exertion, and laughing. 
She suffered from dyspnea secondary to the coughing both 
at rest and on exertion due to her level of bronchial hyper-
reactivity. In terms of medication, she was taking high-dose 
inhaled Pulmicort®, formoterol, ipratropium, and regular 
nonsteroidal anti-inflammatory analgesia and tramadol for 
chest wall pain, along with omeprazole. She would nebulize 
Ventolin® and Atrovent® according to need. She fulfilled all 
clinical criteria for the diagnosis of RADS.1
A repeat of her tests was impossible due to her intractable 
coughing. However, she did undergo a bronchoscopy at our 
center, which showed the entire bronchial tree mucosa to be 
deeply erythematous with widespread petechial hemorrhage. 
Due to the irritant effects of the disinfectants in the endoscopy 
suite, severe aggravation of her coughing occurred on her 
arrival, making the procedure very difficult, and precluding 
the chance of a biopsy.
She was commenced on prednisolone 60 mg daily, 
along with her regular inhalers. Lidocaine nebulizers 
were trialed without therapeutic benefit. Inhaled sodium 
  cromoglycate, oral antihistamines, and antileukotrienes 
were also tried   without benefit. She subsequently received 
a trial of azithromycin and pulsed methylprednisolone also 
without benefit. Her total immunoglobulin G levels were 
below normal at 4.4 g/L (normal range 6–16 g/L) without 
any other immune defect, and intravenous immunoglobulin 
(Vigam®) was given without benefit. Antiviral drugs were 
tried   followed by cotrimoxazole without benefit, with trials 
lasting several weeks. It was then decided to try immunosup-
pression with cyclosporine. This appeared to increase her 
symptoms by 3 months, and at 4 months it was discontinued. 
This completed at least 12 months of trials with different 
treatments, without any hint of improvement.
At this stage, the immunological properties of vitamin D 
were being reported, and we began a trial of high-dose oral 
vitamin D 2000 IU/day. Vitamin D levels were requested, 
but her local hospital did not routinely perform this test. 
As a result, measurement at our hospital was arranged at 
her next visit. This showed a vitamin D level of 57 nmol/L 
at eight weeks after commencing the high dose. Scientific 
data from osteoporosis research shows a rise of 8–10 nmol 
each month on a vitamin D dose of 1000 IU/day. This would 
suggest that our patient’s vitamin D level was ,25 nmol/L, 
initially   consistent with severe deficiency. History-taking 
confirmed no ingestion of oily fish and no sunlight   exposure or 
sunbathing for many years. At the start of vitamin D therapy, 
her symptoms were severe with incessant cough and bronchial 
hyper-reactivity as described before, which made measure-
ment of formal lung function difficult. Her chest remained 
clear on physical examination, and she had a C-reactive 
protein of 0.2 and an immunoglobulin E of 9 kU/L.
Despite no other adjustment to her regular   medication 
regime, she noticed an improvement in her   symptoms once 
her 25-hydroxyvitamin D blood levels were .100 nmol/L. 
  Initially the paroxysms of cough abated, followed by resolution 
of dyspnea on exertion at vitamin D   levels .150 nmol/L. 
We were then able to measure formal lung function tests 
reliably for the first time. Her vitamin D levels took 
6 months to rise to 200 nmol/L. At that point symptoms 
resolved, and weaning of nebulizers, steroids,   nonsteroidal 
anti-inflammatory drugs, and other painkillers could 
  commence, because chest wall pains due to incessant 
cough eased. Figure 1 demonstrates her serum vitamin D 
levels, and highlights the symptomatic improvement and 
spirometry.
At two years, the patient remains largely asymptomatic 
and is rebuilding her life. Her lung function tests one year 
later are normal (forced vital capacity 117%, vital   capacity 
100%, TLCO (transfer factor of the lung for carbon 
monoxide) 97%, forced expiratory flow 25%–75% 110%), 
apart from a residual volume of 182% of predicted which 
has remained unchanged on several repeat measurements. 
A recent methacholine test gave a PC20 of 32 mg/mL.
High-dose vitamin D has been continued and blood 
  levels have remained at 150–200 nmol/L with normal cal-
cium   levels. There are no reported adverse effects of regular 
vitamin D at doses of up to 5000 IU/day. The current recom-
mendation for adults is now 1000 IU/day. There were no side 
effects of the vitamin D, but oral preparations are known to 
have a mild laxative effect and increase skin oils that may 
cause spots.
Discussion
We all live or work in an increasingly chemical environment, 
where uncontrolled inhalational exposures to toxic materials 
could affect our respiratory system acutely. The risk of toxic 
household cleaning products, paints, and resins may not be 
well recognized by the general public, unlike that in industry 
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RADS is a condition which currently lacks clarity,2,18 
with the main difficulties related to retrospective diagnosis 
of a condition following an unmeasured exposure to a 
respiratory irritant. Animal models to establish the exact 
nature and natural history are still awaited, but should assist 
our understanding of whether this is an asthma variant or a 
different disease state. While the literature contains increasing 
numbers of reported cases from an expanding array of causal 
agents, it lacks any guidance on effective treatment, especially 
for those patients with ongoing symptoms who have a very 
poor quality of life.
The effects of vitamin D as a hormone have gained atten-
tion in the literature over the last 2–3 years.   Vitamin D appears 
to have regulatory effects on every part of the immune 
system, with vitamin D deficiency being linked to an array 
of immunologically based diseases.19 Because Vitamin D 
promotes steroid sensitivity in the body and can downregulate 
an inflammatory state via gene expression and cytokine pro-
duction, its action in this case could be directly on the airway. 
Vitamin D receptors are present in the airways and are thought 
to inhibit proinflammatory cytokines, with effects on CD4+ T 
cells, interleukin-2, interferon-gamma, and macrophages.20,21 
A deficiency of Vitamin D could be associated with an inabil-
ity to switch off the inflammatory state, following an acute 
inhalational insult, with upregulation of prostaglandin, leu-
kotrienes, macrophages, and T cell activity and recruitment. 
Vitamin D receptor polymorphisms are gaining attention as 
a cause of vitamin D insensitivity in respiratory diseases, 
which can be overcome by high doses. In our case, vitamin 
D deficiency was present because   optimal blood levels 
should be .75 nmol/L. Recent data suggests higher values 
(.150 nmol/L) are needed for optimal immune health.
We had no histological biopsies from our case, but 
  considered her to fulfill all criteria for RADS. This case 
  presented a difficult management problem, and was refractory 
to all conventional treatments, with devastating effects on 
employment. The responses to vitamin D were slow and 
progressive, and effects appeared optimal when blood levels 
were .150 nmol/L. These observations would support a 
trial of high-dose oral vitamin D in similar cases of RADS 
refractory to asthma treatment. If this experience is repeated, 
it may assist our understanding of the condition and possible 
disease mechanisms, via the anti-inflammatory effects of 
vitamin D, and offer a treatment.
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